Posters
Uveal and capsular biocompatibility of a new hydrophobic acrylic microincision intraocular lens
Poster Details
First Author: L.Werner USA
Co Author(s): V. Balendiran N. Ellis C. Shumway B. Jiang K. Kamae N. Mamalis
Abstract Details
Purpose:
To evaluate uveal biocompatibility and capsular bag opacification of a new hydrophobic acrylic microincision intraocular lens (IOL) in comparison to a commercially available single-piece hydrophobic acrylic lens.
Setting:
John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA.
Methods:
Eight New Zealand rabbits had bilateral phacoemulsification and implantation of the preloaded Nanex™ multiSert+™ IOL in one eye and a commercially available preloaded lens (AcrySof® IQ in UltraSert™, model AU00T0) in the contralateral eye. Slit lamp examination was performed weekly for 4 weeks. The rabbits were then humanely euthanized and their globes enucleated. Capsular bag opacification was assessed from the Miyake-Apple view, and the eyes underwent histopathologic evaluation.
Results:
Postoperative inflammatory reactions were similar between test and control eyes. Mean postmortem central PCO was 0.93 ± 0.73 in the test group and 1.19 ± 0.53 in the control group. Peripheral PCO was 1.75 ± 0.92 in the test group and 2.06 ± 0.77 in the control group. Central and peripheral PCO scores were not statistically different between test and control groups (P = 0.41 and P = 0.35 respectively; two-tailed t-test paired two sample for means).
Conclusions:
A new microincision IOL incorporating an ultraviolet-ozone treatment on the posterior surface performed similarly to a commercially available single-piece hydrophobic acrylic IOL in terms of uveal and capsular biocompatibility in the rabbit model. This is the first hydrophobic acrylic microincision IOL to demonstrate similar PCO performance to a conventional IOL.
Financial Disclosure:
receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented
